OCGN
NASDAQ · Biotechnology
Ocugen Inc
$1.06
+0.03 (+2.91%)
Financial Highlights (FY 2026)
Revenue
4.84M
Net Income
-74,469,925
Gross Margin
—
Profit Margin
-1,537.4%
Rev Growth
—
D/E Ratio
0.97
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 53.1% | 53.1% | 53.1% |
| Operating Margin | -1,425.7% | -9.1% | -7.4% | -8.5% |
| Profit Margin | -1,537.4% | -7.8% | -9.5% | -10.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 4.84M | 214.85M | 205.76M | 219.05M |
| Gross Profit | — | 114.00M | 109.18M | 116.23M |
| Operating Income | -69,058,626 | -19,531,624 | -15,277,626 | -18,612,053 |
| Net Income | -74,469,925 | -16,849,465 | -19,542,916 | -21,937,521 |
| Gross Margin | — | 53.1% | 53.1% | 53.1% |
| Operating Margin | -1,425.7% | -9.1% | -7.4% | -8.5% |
| Profit Margin | -1,537.4% | -7.8% | -9.5% | -10.0% |
| Rev Growth | — | +3.8% | +8.3% | +19.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 85.88M | 133.66M | 136.59M | 175.58M |
| Total Equity | 88.76M | 321.72M | 302.90M | 309.38M |
| D/E Ratio | 0.97 | 0.42 | 0.45 | 0.57 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -66,429,809 | -26,350,714 | -23,624,019 | -24,403,723 |
| Free Cash Flow | — | -15,177,197 | -13,829,123 | -11,832,953 |